JPRN-UMIN000030548已完成未知
Comparison of Dapagliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized,Open-Label, Active-Controlled Trial - Comparison of Dapagliflozin and Pioglitazone Effects on NAFLD and NASH in Patients With Type 2 Diabetes: A Randomized Trial
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients with diabetes complications
研究者
相似试验
尚未招募
4 期
Comparison of Dapagliflozin and Pioglitazone for Non-Alcoholic Fatty Liver Disease in Type 2 DiabetesCTRI/2024/07/071087Babra
招募中
3 期
Effects of Dapagliflozin and Empagliflozin in Myocardial DysfunctioHeart failureIRCT20111206008307N45Tabriz University of Medical Sciences75
尚未招募
2 期
Comparing the effect of Empagliflozin, Pioglitazone and their combination, on the course of non-alcoholic fatty liver disease in diabetic patientson-alcoholic fatty liver disease.Fatty (change of) liver, not elsewhere classifiedK76.0IRCT20230903059343N1Arak University of Medical Sciences120
招募中
3 期
Safety and efficacy of Dapagliflozin and sitagliptin in elderly uncontrolled type 2 diabetes mellitus patientsCTRI/2023/06/053833Dr Mukku Venkata Pratap Reddy
已完成
不适用
The study of dapagliflozin versus sitagliptin treatment efficacy on preventing cardiovascular risk factors in type 2 DM patients (DIVERSITY-CVR study)Type 2 Diabetes MellitusJPRN-UMIN000028014the Japan Society for Patient Reported Outcome (PRO)340